Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy.

Cell Rep Med · 2025 · PMC12711662 · PMID 41197618

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Compared to the control group, there was no significant change in the anti-PD-1 group; however, there was an increasing trend in the trilaciclib monotherapy group, and the expansion was obvious in the combined treatment group ( Figures S17 G and S17H).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.